Novel peptides for preventing or treating bone diseases and use thereof

Abstract

The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 15 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.

1 . A peptide comprising the amino acid sequence of SEQ ID NO: 1. 
     
     
         2 . (canceled) 
     
     
         3 . The peptide of  claim 1 , wherein the peptide decreases an expression level of an adhesion factor for a bone marrow hematopoietic stem cell and mobilizes the bone marrow hematopoietic stem cell in bone marrow to a bloodstream. 
     
     
         4 . The peptide of  claim 1 , wherein the peptide decreases osteoclasts in the bone marrow. 
     
     
         5 . A polynucleotide encoding a peptide of  claim 1 . 
     
     
         6 - 9 . (canceled) 
     
     
         10 . The peptide of  claim 1  that consists of the amino acid sequence set forth in SEQ ID NO: 1. 
     
     
         11 . A pharmaceutical composition comprising the peptide of  claim 1  and a pharmaceutically acceptable carrier, excipient, and diluent. 
     
     
         12 . The pharmaceutical composition of  claim 10 , that is formulated for oral administration. 
     
     
         13 . The pharmaceutical composition of  claim 10 , that is formulated for parenteral administration.